RianJasonDicksteinMDF.A.C.S.

Surgical Oncology

Clinical Assistant Professor, Surgery, University of Maryland School of Medicine

Dr. Dickstein is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Office
7580 Buckingham Blvd
Suite 110
Hanover, MD 21076
Phone+1 410-760-9400

Fax+1 410-787-1911

University of Texas M D Anderson Cancer CenterFellowship, Urologic Surgical Oncology, 2010 - 2012
Boston University Medical CenterResidency, Urology, 2006 - 2010
Boston University Medical CenterInternship, Transitional Year, 2005 - 2006
Rutgers Robert Wood Johnson Medical SchoolClass of 2005

PubMed

3 citations
Oncolytic adenoviral therapy plus pembrolizumab in BCG-unresponsive non-muscle-invasive bladder cancer: the phase 2 CORE-001 trial.
Roger Li, Paras H Shah, Tyler F Stewart, Jong Kil Nam, Trinity J Bivalacqua
Nature Medicine. 2024-08-01
1 citations
Interruptions in bladder cancer care during the COVID-19 public health emergency.
John L Gore, Kristin Follmer, Jason Reynolds, Michael Nash, Christopher B Anderson
Urologic Oncology. 2024-04-01
62 citations
Use of Fluorescence In Situ Hybridization to Predict Response to Bacillus Calmette-Guérin Therapy for Bladder Cancer: Results of a Prospective Trial
Ashish M. Kamat, Rian J. Dickstein, Fabrizio Messetti, Roosevelt Anderson, Shanna Pretzsch
The Journal of Urology. 2012-03-01

UMMS in the NewsApril 15th, 2021
Phase 3 Registration Trial for Non-Muscle Invasive Bladder Cancer Achieves 42% Complete Response Rate at Three Months in Carcinoma in Situ PatientsMay 21st, 2018